Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Italia
    • Utenti registrati
    • 0039 0424-472449 Richiedi informazioni
    • 0039 0424-472449 Richiedi informazioni
    ItalyItaly
      • Part of brands: |
        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        Genomics Precision Diagnostic > Oncology > Prostate Cancer

        Prostate Cancer

        Prostate cancer is the second most common cancer in men after skin cancer and the second leading cause of cancer death in men after lung cancer. Risk factors for prostate cancer include increased age, family history and black race
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Prostate cancer is the second most common cancer in men after skin cancer and the second leading cause of cancer death in men after lung cancer. Risk factors for prostate cancer include increased age, family history and black race. In early stages, prostate cancer is asymptomatic and is typically detected by screening. Although many prostate cancers are sporadic, about 5-15% of prostate cancer diagnoses may be associated with a strong hereditary component. Genetic testing has found its place in routine testing for breast, ovarian and prostate cancers amongst others, providing actionable preventive measures to increase life expectancy and quality of life.
        • Hereditary cancer syndromes are encountered in all medical specialties. Although they account for about 5% of all malignancies, it is of special importance to identify these patients because, unlike patients with sporadic cancers, they require special, long-term care as their predisposition can cause them to develop certain tumors at a relatively early age. Most hereditary cancers are associated with a “germline mutation” that will be present in every cell of the human body. Identification of patients at risk of inherited cancer susceptibility is dependent upon the ability to characterize genes and alterations associated with increased cancer risk as well as gathering a detailed personal and family history aiding in the identification of the mode of inheritance as well as other family members at risk of suffering from this susceptibility. Most hereditary cancer syndromes follow an autosomal dominant inheritance, and the penetrance is high.
        • The Igenomix Prostate Cancer Precision Panel provides a comprehensive analysis of the most common genes responsible for the development of a malignant growth in the prostate using next-generation sequencing (NGS) to fully understand the spectrum of relevant lung cancer predisposition genes.

        Indication

        The Igenomix Comprehensive Inherited Caner Precision Panel is indicated as a screening and diagnostic test in those cases where there are: 

        • Family history of prostate cancer
        • Blood in the urine
        • Frequent urination  
        • Urge to urinate
        • Pain or burning during urination
        • Weak or interrupted urine flow
        • Fatique
        • Lower back pain
        • Change in bowel habits
        • Unintentional weight loss

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular diagnosis for an accurate clinical diagnosis of a patient with personal or family history suggestive of a hereditary cancer syndrome with predisposition to prostate cancer.
        • Early initation of treatment with a multidisciplinary team for appropriate total body screening, early surgical intervention, or pharmacologic treatment. 
        • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
        • Reduce morbidity related toprostate cancer, or morbidity secondary to complications of surveillance and treatment.
        • Categorization of genetic alterations into predictive levels of standard, investigational or hypothetic target therapies in the molecular pathology reports.
        • Improved pathways from diagnosis to treatment in susceptible populations.

        Genes & Diseases

        Methodology

        References

        See scientific referrals

        National Comprehensive Cancer Network.  (2021). Retrievedfrom https://www.nccn.org/professionals/physician_gls/default.aspx#detection

        Zhen, J. T., Syed, J., Nguyen, K. A., Leapman, M. S., Agarwal, N., Brierley, K., Llor, X., Hofstatter, E., &Shuch, B. (2018). Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer, 124(15), 3105–3117. https://doi.org/10.1002/cncr.31316

        Heidegger, I., Tsaur, I., Borgmann, H., Surcel, C., Kretschmer, A., Mathieu, R., Visschere, P., Valerio, M., van den Bergh, R., Ost, P., Tilki, D., Gandaglia, G., Ploussard, G., & EAU-YAU Prostate Cancer Working Party (2019). Hereditary prostate cancer – Primetime for genetic testing?. Cancer treatment reviews, 81, 101927. https://doi.org/10.1016/j.ctrv.2019.101927

        Pilarski R. (2019). The Role of BRCATesting in Hereditary Pancreatic and Prostate Cancer Families. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 39, 79–86. https://doi.org/10.1200/EDBK_238977

        Tan, S. H., Petrovics, G., &Srivastava, S. (2018). Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. International journal of molecular sciences, 19(4), 1255. https://doi.org/10.3390/ijms19041255

        Heise, M., & Haus, O. (2014). Dziedzicznyrakgruczołukrokowego [Hereditary prostate cancer]. Postepyhigieny i medycynydoswiadczalnej (Online), 68, 653–665. https://doi.org/10.5604/17322693.1104682

        Pritzlaff, M., Tian, Y., Reineke, P., Stuenkel, A. J., Allen, K., Gutierrez, S., Jackson, M., Dolinsky, J. S., LaDuca, H., Xu, J., Black, M. H., & Helfand, B. T. (2020). Diagnosing hereditary cancer predisposition in men with prostate cancer. Genetics in medicine : official journal of the American College of Medical Genetics, 22(9), 1517–1523. https://doi.org/10.1038/s41436-020-0830-5

         

        descargar

        Detail description

        Download

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        GUIDA

        Fertilità
        Prevenzione di malattie ereditarie
        Gravidanza serena

        I NOSTRI SERVIZI

        Soluzioni genetiche
        Informazioni sulla genetica

        PANORAMICA

        Informazioni su Igenomix
        Contatti
        Come inviare un campione
        Qualità
        Lavora con noi
        News and Press

           0039 0424-472449
        Contatti
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        Linguaggio

        [2019] © Igenomix Politica sulla privacyPolitica qualità Politica dei cookie       Soddisfazione       Manuale dell’utente

        Richiedi informazioni








        • reCAPTCHA demo: Simple page











        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        • Italia
        • Utenti registrati
        • Area pazienti
        • Area cliniche

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        Italy
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.